> Presentation of results from seven new studies focusing on multigene Oncotype DX breast cancer test
Genomic Health announced results from seven new studies focusing on its multigene Oncotype DX breast cancer test, which has helped guide treatment decisions in more than 175,000 breast cancer patients worldwide.
The results, presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, SABCS, further confirm the clinical value associated with the Oncotype DX Recurrence Score in accurately predicting chemotherapy benefit and recurrence risk in early-stage breast cancer patients.
A meta-analysis of seven studies, with a total of 912 patients, demonstrated a consistent impact of the Recurrence Score on breast cancer adjuvant treatment decisions.
The results of this meta-analysis indicate that the Recurrence Score provides key information for treatment decision-making that cannot be ascertained from traditional measures.
Oncotype DX Recurrence Score is the best predictor of chemotherapy benefit in estrogen receptor-positive breast cancer.